Back to top
more

Novo Nordisk (NVO)

(Delayed Data from NYSE)

$111.94 USD

111.94
4,553,843

-0.01 (-0.01%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $111.97 +0.03 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Kinjel Shah headshot

Pharma Stock Roundup: BAYRY's Q1 Earnings, JNJ's New Buyout, Pipeline Updates

by Kinjel Shah

Bayer (BAYRY) releases Q1 results. J&J (JNJ) set to acquire private biotech, Proteologix, which will add atopic dermatitis candidates.

Sundeep Ganoria headshot

4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly

by Sundeep Ganoria

Though obesity drugs continue to gain traction, it is currently a duopoly market. As analysts expect demand to grow at an encouraging pace, several biotech/pharma companies are rushing to enter this space.

Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.

Kinjel Shah headshot

3 Drug Stocks to Watch on Raised 2024 Earnings & Sales Guidance

by Kinjel Shah

Here we discuss three drugmakers, Eli Lilly and Company (LLY), Novo Nordisk (NVO) and Merck (MRK), that have raised their earnings as well as sales guidance for 2024.

Roche (RHHBY) Posts Encouraging Phase I Obesity Drug Data

by Zacks Equity Research

Data from the study shows that nearly half of the patients who received Roche's (RHHBY) subcutaneously-administered obesity drug lost more than 20% of their body weight after 24 weeks.

Should You Hold Viking Therapeutics (VKTX) in Your Portfolio?

by Zacks Equity Research

Viking Therapeutics' (VKTX) lead candidate for obesity, VK2735, is expected to have tremendous potential. However, existing competition from obesity drugs in the market remains a woe.

Eli Lilly (LLY) Settles With Spa Selling Mounjaro, Zepbound Copies

by Zacks Equity Research

Eli Lilly (LLY) reaches settlement with a medical spa selling copycat versions of Mounjaro and Zepbound. The spa will make a monetary payment to Lilly.

Here's Why Novo Nordisk (NVO) is a Strong Momentum Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Novo Nordisk (NVO) Up 3% as Haemophilia Drug Meets Study Goals

by Zacks Equity Research

Novo Nordisk's (NVO) shares rise 3.1% as the company meets co-primary endpoints in a late-stage study evaluating its investigational candidate, Mim8, for the treatment of haemophilia A.

Here's Why Novo Nordisk (NVO) is a Strong Growth Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Prothena (PRTA) Q1 Earnings Miss Estimates on Higher R&D Expenses

by Zacks Equity Research

Prothena (PRTA) posts a wider-than-expected loss in the first quarter on lower revenues and higher costs.

Should You Invest in the VanEck Pharmaceutical ETF (PPH)?

by Zacks Equity Research

Sector ETF report for PPH

Wall Street Bulls Look Optimistic About Novo Nordisk (NVO): Should You Buy?

by Zacks Equity Research

According to the average brokerage recommendation (ABR), one should invest in Novo Nordisk (NVO). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Amgen (AMGN) Q1 Earnings Top, Stock Up on Obesity Drug Update

by Zacks Equity Research

Amgen (AMGN) beats first-quarter 2024 estimates for earnings and sales. Amgen is "very encouraged" by interim data from the phase II study on obesity candidate MariTide.

Kinjel Shah headshot

Pharma Stock Roundup: LLY, NVO, PFE Q1 Results, JNJ's New Plan to Resolve Talc Claims

by Kinjel Shah

Eli Lilly (LLY), Novo Nordisk (NVO), Pfizer (PFE) and AbbVie (ABBV) announce their first-quarter results.

Novo Nordisk (NVO) Q1 Earnings Beat, GLP-1 Drugs Boost Sales

by Zacks Equity Research

Novo Nordisk (NVO) reports better-than-expected first-quarter results, beating both earnings and revenues, driven by strong sales of Diabetes and Obesity care products.

Eli Lilly (LLY) Q1 Earnings Top, Sales Miss, 2024 View Raised

by Zacks Equity Research

Eli Lilly (LLY) beats first-quarter estimates for earnings but misses the same for sales. It raises its guidance for 2024 on strong demand for Mounjaro and Zepbound.

Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?

by Zacks Equity Research

Let's look at five large-cap pharma/biotech companies slated to release quarterly results this week.

Should You Invest in Novo Nordisk (NVO) Ahead of Q1 Earnings?

by Zacks Equity Research

Novo Nordisk's (NVO) revenues in the first quarter of 2024 are expected to have been driven by its diabetes and obesity care product sales, especially Ozempic, Rybelsus and Wegovy.

Santanu Roy headshot

Beat the Market the Zacks Way: ADMA Biologics, Carlisle, McCormick Manufacturing in Focus

by Santanu Roy

Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.

Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck and AbbVie

by Zacks Equity Research

Eli Lilly, Novo Nordisk, Merck and AbbVie are part of the Zacks Industry Outlook article.

Novo Nordisk (NVO) Stock Sinks As Market Gains: Here's Why

by Zacks Equity Research

In the latest trading session, Novo Nordisk (NVO) closed at $126.16, marking a -1.93% move from the previous day.

Kinjel Shah headshot

4 Large Drug Stocks to Hold on to Amid Industry Challenges

by Kinjel Shah

Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and AbbVie (ABBV) are worth retaining in one's portfolio.

Kinjel Shah headshot

Should Eli Lilly (LLY) Be in Your Portfolio Ahead of Q1 Earnings?

by Kinjel Shah

Eli Lilly (LLY) enjoys strong fundamentals and is expected to consistently do well, mainly supported by its new drugs and its solid pipeline.

Novo Nordisk (NVO) Boasts Earnings & Price Momentum: Should You Buy?

by Zacks Equity Research

Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.